| Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases (NCT04689074) | Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari | 2021-02-03 |
| RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY (NCT07535385) | Fondazione IRCCS Policlinico San Matteo di Pavia | 2020-08-17 |
| Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (NCT03949894) | Korea Otsuka Pharmaceutical Co., Ltd. | 2019-07-01 |
| Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) (NCT02964273) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2016-09-23 |
| Canadian Medical Assessment of JINARC™ Outcomes Registry (NCT02925221) | Otsuka Canada Pharmaceutical Inc. | 2016-02-26 |
| Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 (NCT02616055) | Kadmon Corporation, LLC | 2015-12-25 |
| Lanreotide In Polycystic Kidney Disease Study (NCT02127437) | Assistance Publique - Hôpitaux de Paris | 2014-09-19 |
| Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease (NCT02225860) | Tufts Medical Center | 2014-05-01 |
| Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT02115659) | Shanghai Changzheng Hospital | 2014-04-01 |
| Study of Lanreotide to Treat Polycystic Kidney Disease (NCT01616927) | University Medical Center Groningen | 2012-06-01 |
| Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (NCT01430494) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2011-06-01 |
| A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] (NCT01280721) | Otsuka Pharmaceutical Co., Ltd. | 2010-11-01 |
| Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency (NCT01223755) | Mario Negri Institute for Pharmacological Research | 2010-09-01 |
| Tolvaptan Extension Study in Participants With ADPKD (NCT01214421) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2010-05-26 |
| Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NCT00346918) | University of Zurich | 2006-06-01 |
| Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (NCT00309283) | Mario Negri Institute for Pharmacological Research | 2006-04-01 |